Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURQUOISE-I: Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir in HCV/HIV-1 Coinfection
NCT01939197Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ombitasvir + paritaprevir + ritonavir and dasabuvir in hepatitis C (HCV) (12 arms), sponsored by AbbVie Inc. Primary endpoint: Sustained Virologic Response 12 Weeks Post-Treatment. Started Aug 2013; status: completed.
02
Drugs
ombitasvir + paritaprevir + ritonavirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01939197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939197.